Related references
Note: Only part of the references are listed.Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial
N. Normanno et al.
ANNALS OF ONCOLOGY (2015)
Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review
James Sherwood et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2015)
KRAS mutations in microsatellite instable gastric tumours: impact of targeted treatment and intratumoural heterogeneity
Pedro Queiros et al.
VIRCHOWS ARCHIV (2015)
Cell Plasticity and Heterogeneity in Cancer
Nemanja D. Marjanovic et al.
CLINICAL CHEMISTRY (2013)
Molecular patterns in the evolution of serrated lesion of the colorectum
Timo Gaiser et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens
D. Gonzalez de Castro et al.
BRITISH JOURNAL OF CANCER (2012)
Concordant KRAS Mutations in Primary and Metastatic Colorectal Cancer Tissue Specimens: A Meta-Analysis and Systematic Review
Cheng-Bo Han et al.
CANCER INVESTIGATION (2012)
Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers
Yu Imamura et al.
CLINICAL CANCER RESEARCH (2012)
KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment
Florence Boissiere-Michot et al.
MODERN PATHOLOGY (2012)
Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial
Claus Roedel et al.
LANCET ONCOLOGY (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Does Neoadjuvant Therapy Alter KRAS and/or MSI Results in Rectal Adenocarcinoma Testing?
Sarah L. Ondrejka et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2011)
Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls
Aude Lamy et al.
MODERN PATHOLOGY (2011)
Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing
Susan D. Richman et al.
ANALYTICAL CELLULAR PATHOLOGY (2011)
KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy
Jochen Gaedcke et al.
RADIOTHERAPY AND ONCOLOGY (2010)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer
Salvatore Artale et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
Astrid Lievre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Cellular responses to EGFR inhibitors and their relevance to cancer therapy
Pinaki R. Dutta et al.
CANCER LETTERS (2007)
KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression
C. Oliveira et al.
ONCOGENE (2007)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Preoperative versus postoperative chemoradiotherapy for rectal cancer
R Sauer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Universal, robust, highly quantitative SNP allele frequency measurement in DNA pools
N Norton et al.
HUMAN GENETICS (2002)
Share Paper
